<DOC>
	<DOCNO>NCT01847729</DOCNO>
	<brief_summary>The aim study determine current prevalence co-addictions , include problem/pathological gambling , patient receive Opiate Substitution Treatment ( OST ) , compare patient receive OST without co-addiction ( exclude tobacco dependence ) order determine clinical profile . In addition , ancillary study carry among patient receive methadone , aim etablish whether low plasma concentration methadone , one hand , ultrarapid metabolizer genetic profile , , characteristic commonly associate presence co-addictions . This allow u complete patient 's pharmacological characterization .</brief_summary>
	<brief_title>OPAL : `` Opiates PhArmacoLogy ''</brief_title>
	<detailed_description>Non-interventionel study Total duration : 12 month ( preparation , recruitment , analysis ) Recruitment period : 6 month Duration monitor per patient : monitoring Main objective : assess current prevalence addictive co-morbidities opiate-dependent subject receive Opiate Substitution Treatment ( OST ) least 6 month . Secondary objective : compare patient treat use OST currently co-addiction ( exception tobacco dependence ) patient treat OST currently co-addiction , base pharmacological clinical characteristic ( pharmacological characteristic : pharmacokinetic pharmacogenetic analysis part ancillary study patient treat methadone ) . Main judgment criterion : Presence absence co-addictions ( except tobacco dependence ) , determine use assessment tool . The secondary assessment criterion shall : sociodemographic data , data opiate dependence , data substance use disorder , data gamble practice , psychopathological data ( impulsivity , ADHD ) , pharmacokinetic data pharmacogenetic data . Statistical analysis : For main judgment criterion , rate prevalence current co-addictions estimate use 95 % confidence interval . Descriptive analysis carry variable gather along point estimate 95 % confidence interval qualitative quantitative variable . The second stage involve univariate exploratory analysis . The two group patient compare accord presence absence co-addictions . For quantitative variable Student test non parametric test use . For qualitative variable , use Chi-squared Fisher test . Finally , multivariate analysis carry . The factor previously identify link co-addictions ( threshold p = 0.2 ) incorporate logistic regression model . The best model , wich enable explanation co-addictions select use likelihood ratio test .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<criteria>General Over 18 , Under treatment unsing methadone buprenorhine ( +/ naloxone ) morphine substitute , prescribed opiate dependence , OST begin least 6 month previously , Incarceration less month event monitoring SMPR , Good understand French , able read write . General non Protected adult ( guardianship , wardship ) Disorder higherorder brain function ( severe cognitive disorder confusion ) psychotic disorder ( hallucination , delusion ) may interfere study . NonInclusion criteria patient participate ancillary study : Medical monitoring doctor Drug Addiction Network Nantes Area , OST methadone Adjustement dosage 5 day prior administer OST Pregnant woman Absence social security registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Opiate dependence</keyword>
	<keyword>Opiate substitution treatment</keyword>
	<keyword>co-addictions</keyword>
	<keyword>Patients addict opiate</keyword>
	<keyword>methadone</keyword>
	<keyword>buprenorhine</keyword>
	<keyword>morphine</keyword>
	<keyword>OST place</keyword>
	<keyword>pathological gambling</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacogenetic</keyword>
	<keyword>polymorphism</keyword>
	<keyword>cytochrome P450 2D6</keyword>
	<keyword>Therapeutic Drug Monitoring</keyword>
</DOC>